Download this Press Release as a PDF Oxford, UK – 10th February 2025 – IngenOx Therapeutics, the Oxford-based biopharmaceutical company, announcedthat its Chief Medical Officer, Professor David Kerr CBE, met with Chinese Premier Li Qiang on 26 January 2025 at…
IngenOx Therapeutics, the Oxford biopharma company focused on developing novel cancer therapeutics, provided today a company update on its board reshuffle. In the revised board, Patrick Soon-Shiong, M.D. joins as Chairman. Leonard S. Sender, M.D. and Sandeep “Bobby” Reddy, M.D.…
Oxford, UK – 07 Dec 2023 Download this Press Release as a PDF IngenOx Therapeutics, an Oxford-based biopharmaceutical company, announced that its Chief Medical Officer, Prof. David Kerr had published a review on the use of diagnostic biomarkers to personalise…
Oxford, UK – 6 October 2023 Download this Press Release as a PDF IngenOx Therapeutics, the Oxford-based biopharmaceutical company announced today that it had received separate grants of applications from the Chinese (CNIPA); and European Patent Office for compounds and…
Oxford, UK – 6 July 2023 Download this Press Release as a PDF IngenOx Therapeutics, an Oxford-based clinical-stage biopharma company, has been granted patents for new compounds that inhibit PRMT5. The new patents are for the composition of matter…
Download Press Release as a PDF IngenOx Therapeutics, the Oxford biopharma company announced today that the Hong Kong Drug Office had given approval for a Phase II clinical trial to proceed in treatment-resistant hepatocellular cancer (HCC) patients, combining its drug…
Download Press Release as a PDF IngenOx Therapeutics, the clinical stage Oxford biopharma company announced today the results of collaborative work between the University of Oxford using its zabadinostat drug. In experimental models, zabadinostat was found to potentiate both the…
Celleron Therapeutics and Argonaut Therapeutics have jointly announced today the completion of a merger agreement to form IngenOx Therapeutics. Supported by Oxford Science Enterprises (OSE), the merger of the two University of Oxford spinout companies brings together drug discovery and…